Bresso Site_GMP

Surface area: about 3.300mq (35.000 SQF) divided in two floors
Designed and built in accordance with the highest quality standards
First Floor: 1.600mq (17.000SQF) dedicated to development, testing and quality control
Second Floor: 1.700mq (18.000SQF) dedicated to the production of viral vectors and Genetically modified cells according to cGMP
10 Grade B suites and 7 Grade C suites
Authorization for the GMP production of viral vectors (on a 48L or 200L scale) and genetically modified cells for clinical trials and market

Subscribe to press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.

Bresso Site_GMP

Subscribe to press releases

About us

About us ▾

Pipeline

Pipeline ▾

GMP Solutions

GMP Solutions ▾

Investors

Investors ▾

Governance

Governance ▾

News & Events

News ▾